Preclinical safety, toxicology, and biodistribution study of adenoviral gene therapy with sVEGFR-2 and sVEGFR-3 combined with chemotherapy for ovarian cancer.

Human gene therapy. Clinical development

Volumn 24, Issue 1, 2013, Pages 29-37

  Tuppurainen, Laura ^a   Sallinen, Hanna ^b   Kokki, Emmi ^b   Koponen, Jonna ^b   Anttila, Maarit ^b   Pulkkinen, Kati ^b   Heikura, Tommi ^b   Toivanen, Pyry ^b   Hämäläinen, Kirsi ^b   Kosma, Veli Matti ^b   Heinonen, Seppo ^b   Alitalo, Kari ^b   Ylä Herttuala, Seppo ^b  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

ADENOVIRUS; ANIMAL; ARTICLE; BLOOD; BLOOD ANALYSIS; DRUG SCREENING; FEMALE; GENE THERAPY; GENE VECTOR; GENETICS; HUMAN; LIVER; LUNG; METABOLISM; OVARY TUMOR; PATHOLOGY; RAT; TISSUE DISTRIBUTION;

ADENOVIRIDAE; ANIMALS; ANTINEOPLASTIC AGENTS; BLOOD CHEMICAL ANALYSIS; DRUG EVALUATION, PRECLINICAL; FEMALE; GENETIC THERAPY; GENETIC VECTORS; HUMANS; LIVER; LUNG; OVARIAN NEOPLASMS; RATS; TISSUE DISTRIBUTION; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-3;

EID: 84886741460     PISSN: None     EISSN: 23248645     Source Type: None    
DOI: 10.1089/humc.2013.006     Document Type: Article

References (0)